Aura Biosciences, Inc.
AURA
$6.51
$0.213.33%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.58% | 11.52% | 16.34% | 15.46% | 10.83% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.78% | 20.30% | 17.05% | 13.09% | 19.62% |
| Operating Income | -21.78% | -20.30% | -17.05% | -13.09% | -19.62% |
| Income Before Tax | -28.15% | -25.77% | -20.58% | -13.81% | -17.16% |
| Income Tax Expenses | -48.67% | -27.32% | -53.55% | -17.52% | -- |
| Earnings from Continuing Operations | -27.94% | -25.65% | -20.40% | -13.76% | -17.48% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -27.94% | -25.65% | -20.40% | -13.76% | -17.48% |
| EBIT | -21.78% | -20.30% | -17.05% | -13.09% | -19.62% |
| EBITDA | -22.19% | -20.71% | -17.37% | -13.38% | -20.00% |
| EPS Basic | -11.54% | -9.26% | -2.01% | 9.15% | 11.27% |
| Normalized Basic EPS | -11.42% | -9.07% | -1.87% | 9.34% | 10.82% |
| EPS Diluted | -11.54% | -9.26% | -2.01% | 9.15% | 11.27% |
| Normalized Diluted EPS | -11.42% | -9.07% | -1.87% | 9.34% | 10.82% |
| Average Basic Shares Outstanding | 15.88% | 14.25% | 17.12% | 25.32% | 32.56% |
| Average Diluted Shares Outstanding | 15.88% | 14.25% | 17.12% | 25.32% | 32.56% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |